Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Company Overview - Regeneron Pharmaceuticals, Inc. is a biotechnology company based in Tarrytown, New York, with a market capitalization of approximately $82.6 billion, focusing on transformative medicines for serious diseases [1] - The company is classified as a "large-cap" stock, recognized for its diverse portfolio of innovative medicines and breakthrough therapies [2] Stock Performance - Regeneron shares have decreased by 4.8% from their 52-week high of $821.11 reached on January 9 [3] - Over the past 52 weeks, the stock has gained 11.2%, underperforming the Nasdaq Composite's 22.2% returns, but is up 1.3% year-to-date, outperforming the Nasdaq's 2.5% decline [4] - The stock has been trading above the 50-day moving average since mid-July 2025 and above the 200-day moving average since late October [4] Market Sentiment and Analyst Ratings - The stock's recent climb is attributed to positive regulatory developments, strong investor sentiment, and optimism surrounding FDA approvals for key products like Eylea HD, Dupixent, and Libtayo [6] - Analysts maintain a strong optimistic outlook, with a consensus rating of "Strong Buy" from 27 analysts and a mean price target of $870.35, indicating an 11.3% premium to current levels [7] - Despite this, Regeneron has underperformed compared to its rival Amgen Inc., which saw gains of 26.9% over the past 52 weeks [6]